Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols / Development of a magneto-nanosensor (MNS) array for prostate cancer biomarkers

Development of a magneto-nanosensor (MNS) array for prostate cancer biomarkers

Gambhir, SanjivStanford University

No coordinating investigator defined.

No involved investigator sites defined.

G.I. and Other Associated Cancers Research Group

Our goal is to develop a blood-based biomarker magneto-nanosensor array for the accurate early detection and prognostication of prostate cancer

Specific Aim 1: To adapt the magneto-nanosensor array platform to the multiplex measurement of prostate cancer biomarkers for detection and progression. To accomplish this we will functionalize our magneto-nanosensor with capture antibodies for an extended panel of leading biomarker candidates for prostate cancer detection and prognostication rigorously selected from the literature. Initial experiments will be performed to evaluate the performance of the array to detect spiked samples with known quantities of biomarkers, to establish calibration curves, determine the lower limits of detection, and assess reproducibility. Once the array has been completed we will progress to evaluate it using the clinical discovery sample set described in Aim #2. Specific Aim 2: To evaluate the accuracy of the prostate cancer magneto-nanosensor array to classify clinical cancer and control specimens from the Stanford serum bank. For this aim we will test the ability of the array to accurately classify archival serum samples drawn from prostate cancer patients before and after radical prostatectomy, and from patients with positive and negative biopsies. These sera were collected by the PSA analysis laboratory in the Urology Department at the Stanford University Medical Center.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.